TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06774664: A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTC21C in Subjects With Plasma Cell-driven Autoimmune Diseases

Sponsor: Sinocelltech Ltd. · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 99 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,604,025

Rescue Site Savings

+$3,049,800

Unlock Full NCT06774664 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06774664 Rescue Dossier →